Literature DB >> 8204892

BCL2 translocations in leukemias of mature B cells.

M J Dyer1, V J Zani, W Z Lu, A O'Byrne, S Mould, R Chapman, J M Heward, H Kayano, D Jadayel, E Matutes.   

Abstract

Although translocations of the BCL2 gene are frequent in B-cell non-Hodgkin's lymphomas (B-NHL) the incidence, nature, and prognostic significance of similar translocations in the phenotypically related chronic leukemias of mature B cells are unknown. Therefore, we examined 170 cases of B-cell chronic lymphocytic leukemia (B-CLL), 7 cases of B-cell prolymphocytic leukemia (B-PLL), 25 cases of hairy cell leukemia (HCL) and 22 cases of splenic lymphoma with villous lymphocytes (SLVL) with defined cytogenetic abnormalities by DNA blot using both 5' and 3' BCL2 probes to search for rearrangement of the BCL2 locus. Translocation t(14;18) (q32.3;q21.3) was detected cytogenetically in 3 cases of B-CLL. All had breakpoints in the 3' region of BCL2, mapping between the major breakpoint region (MBR) and the minor cluster region (mcr), the breakpoint clusters commonly detected in B-NHL. In 2 of the 3 cases, the breakpoint within BCL2 was mapped to a 1.0-kb EcoRI-HindIII fragment indicating a clustering of breakpoints. Two cases of B-CLL had cytogenetically detectable t(2;18)(p11;q21.3) or t(18;22)(q21.3;q11). Both had rearranged the 5' region of the BCL2 gene to the corresponding lg light-chain gene. Molecular cloning of the t(18;22)(q21.3;q11) showed that the translocation disrupted the BCL2 promoter region and the first untranslated BCL2 exon. Nevertheless, high levels of BCL2 protein were seen in this case. Only 2 other cases in whom cytogenetic analysis was not successful showed rearrangement of the 5' region of BCL2, an overall incidence of 2.3%. No cases of B-PLL, HCL, or SLVL showed either 5' or 3' BCL2 rearrangement. These data confirm the cytogenetic observations that translocations involving the BCL2 locus in all forms of leukemia of mature B cells are rare, and limited to a minor subset of B-CLL. BCL2 translocations in B-CLL involve hot spots of recombination of both the 5' and 3' regions of the BCL2 gene, which are distinct from those commonly seen in B-NHL, suggesting distinct pathogenic mechanisms.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8204892

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Karyotypic and molecular abnormalities in chronic lymphocytic leukaemia.

Authors:  C D Fegan; F E Davies
Journal:  Clin Mol Pathol       Date:  1996-08

Review 2.  The essential role of evasion from cell death in cancer.

Authors:  Gemma L Kelly; Andreas Strasser
Journal:  Adv Cancer Res       Date:  2011       Impact factor: 6.242

Review 3.  Genetics and molecular biology of chronic lymphocytic leukemia.

Authors:  Dennis A Carney; William G Wierda
Journal:  Curr Treat Options Oncol       Date:  2005-05

4.  Immunoglobulin gene translocations in chronic lymphocytic leukemia: A report of 35 patients and review of the literature.

Authors:  Marc DE Braekeleer; Corine Tous; Nadia Guéganic; Marie-Josée LE Bris; Audrey Basinko; Frédéric Morel; Nathalie Douet-Guilbert
Journal:  Mol Clin Oncol       Date:  2016-02-26

5.  High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology.

Authors:  Lauren C Chong; Susana Ben-Neriah; Graham W Slack; Ciara Freeman; Daisuke Ennishi; Anja Mottok; Brett Collinge; Pau Abrisqueta; Pedro Farinha; Merrill Boyle; Barbara Meissner; Robert Kridel; Alina S Gerrie; Diego Villa; Kerry J Savage; Laurie H Sehn; Reiner Siebert; Ryan D Morin; Randy D Gascoyne; Marco A Marra; Joseph M Connors; Andrew J Mungall; Christian Steidl; David W Scott
Journal:  Blood Adv       Date:  2018-10-23

6.  Heterogeneous breakpoints on the immunoglobulin genes are involved in fusion with the 5' region of BCL2 in B-cell tumors.

Authors:  N Yonetani; C Ueda; T Akasaka; M Nishikori; T Uchiyama; H Ohno
Journal:  Jpn J Cancer Res       Date:  2001-09

Review 7.  Venetoclax: evidence to date and clinical potential.

Authors:  Luis Miguel Juárez-Salcedo; Viraj Desai; Samir Dalia
Journal:  Drugs Context       Date:  2019-10-09

8.  Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.

Authors:  Alexander C Leeksma; Justin Taylor; Bian Wu; Thorsten Zenz; Omar Abdel-Wahab; Arnon P Kater; Jeffrey R Gardner; Jie He; Michelle Nahas; Mithat Gonen; Wendimagegn G Alemayehu; Doreen Te Raa; Tatjana Walther; Jennifer Hüllein; Sascha Dietrich; Rainer Claus; Fransien de Boer; Koen de Heer; Julie Dubois; Maria Dampmann; Jan Dürig; Marinus H J van Oers; Christian H Geisler; Eric Eldering; Ross L Levine; Vincent Miller; Tariq Mughal; Nicole Lamanna; Mark G Frattini; Mark L Heaney; Andrew Zelenetz
Journal:  Leukemia       Date:  2018-07-23       Impact factor: 11.528

Review 9.  Exploring the pathways to chronic lymphocytic leukemia.

Authors:  Freda K Stevenson; Francesco Forconi; Thomas J Kipps
Journal:  Blood       Date:  2021-09-09       Impact factor: 25.476

10.  Chronic Lymphocytic Leukemia with t(14;18)(q32;q21) As a Sole Cytogenetic Abnormality.

Authors:  Ghaleb Elyamany; Kamal Fadalla; Hatem Elghezal; Omar Alsuhaibani; Hani Osman; Abdulaziz Al-Abulaaly
Journal:  Clin Med Insights Pathol       Date:  2014-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.